Floatz logo

Acamprosate

Social Anxiety Disorder

Medical University of South CarolinaSmall moleculePhase 4 / ApprovedDormant
BB
66/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
51/ 100
Competitive Position
95/ 100

Competitive context

3 Active assets in the Social Anxiety Disorder cohort.

Asset / SponsorPhaseRating
Vortioxetine
The Medical Research Network
Phase 4BB
Sertraline
Yang I. Pachankis, PhD
Phase 4BB
ALORADINE
VistaGen Therapeutics, Inc.
Phase 3B
Oxytocin
University of Maryland, Baltimore
Phase 2B
Paroxetine
Beijing Tongren Hospital
Phase 1CC
Seroquel®
Centre for Addiction and Mental Health
N/AD
Duloxetine
Yang I. Pachankis, PhD
D

Same molecule, other indications

Acamprosate is also rated in:

alcohol dependenceDormant
BBB
Indicative ·
77 / 100
View asset →
major depressive disorderDormant
BB
Indicative ·
67 / 100
View asset →
generalized anxiety disorderDormant
BB
Indicative ·
66 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →